



中國生物製藥有限公司  
SINO BIOPHARMACEUTICAL LIMITED  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 1177)

26 January 2024

Dear Shareholders,

**New Arrangements on Dissemination of Corporate Communications**

**INTRODUCTION**

Pursuant to new Rule 2.07A<sup>1</sup> of the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the articles of association of Sino Biopharmaceutical Limited (the “Company”), the Company will disseminate the future corporate communications of the Company (the “Corporate Communications”<sup>2</sup>) to the Shareholders<sup>3</sup> electronically and only send Corporate Communications in printed form to the Shareholders upon request.

In this connection, the following arrangements will come into effect from 26 January 2024.

**ARRANGEMENTS**

1. Actionable Corporate Communications<sup>4</sup>

The Company will send the Actionable Corporate Communications to the Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional<sup>5</sup>, the Company will send the Actionable Corporate Communication in printed form together with a request form for soliciting the Shareholder’s functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

2. Corporate Communications

The Company will make the Corporate Communications available on its website ([www.sinobiopharm.com](http://www.sinobiopharm.com)) and the Stock Exchange’s website ([www.hkexnews.hk](http://www.hkexnews.hk)).

A notice of publication of the Website Version<sup>6</sup> of Corporate Communications, in both English and Chinese, will be sent by the Company to the Shareholders by email or by post (only if the Company does not possess the functional email address of a Shareholder) on the publication date of the Corporate Communications.

3. Provision of Shareholder's email address to the Company

In support of electronic communication by email, the Company recommends the Shareholders to complete an online form by scanning above QR Code which is valid by 26 March 2024. Should the Shareholders, if for any reason, have difficulty in gaining access to the online form, they may provide the Company with their email address at any time in future by reasonable notice in writing to the Company's branch share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to [is-ecom@hk.tricorglobal.com](mailto:is-ecom@hk.tricorglobal.com).

It is the responsibility of the Shareholders to provide email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

4. Request for Corporate Communications and Actionable Corporate Communications in printed form

For those Shareholders who wish to receive a printed version of all future Corporate Communications and Actionable Corporate Communications or, if for any reason, have difficulty in gaining access to the Company's website, the Company will, upon receipt of request in writing by the Shareholders to the Company's branch share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to [is-ecom@hk.tricorglobal.com](mailto:is-ecom@hk.tricorglobal.com), send future Corporate Communications and/or the relevant Corporate Communications (as the case may be) to such Shareholders in printed form free of charge.

Details of the arrangements (i) for dissemination of Corporate Communications and (ii) for requesting printed copy of Corporate Communications are published under the "Investor Relations" section in the Company's website ([www.sinobiopharm.com](http://www.sinobiopharm.com)). For any queries in relation to this letter, please call the Company's branch share registrar in Hong Kong, Tricor Tengis Limited, at +852 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays, or send an email to [is-ecom@hk.tricorglobal.com](mailto:is-ecom@hk.tricorglobal.com).

Yours faithfully,  
For and on behalf of  
**Sino Biopharmaceutical Limited**  
**Chan Oi Nin Derek**  
Company Secretary

<sup>1</sup> With effect from 31 December 2023.

<sup>2</sup> Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of the Company's securities or the investing public, including but not limited to (a) the directors' report and the annual accounts together with auditors' report and, where applicable, summary financial report; (b) the interim report and, where applicable, summary interim report; (c) the quarterly report, if any; (d) notice of meeting; (e) listing document; (f) circular; and (g) proxy form.

<sup>3</sup> Holder(s) of securities of the Company.

<sup>4</sup> Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as the Company's Shareholders.

<sup>5</sup> It is the responsibility of a Shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

<sup>6</sup> The version of Corporate Communications being published, in both English and Chinese, on the Company's website.